Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.

Author(s): Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM

Affiliation(s): Department of Psychiatry, Hospital de Princeps d'Espanya, Barcelona, Spain.

Publication date & source: 1992-11, Br J Psychiatry., 161:665-70.

Publication type: Clinical Trial; Randomized Controlled Trial

A double-blind clinical trial of clomipramine versus phenelzine was carried out on 30 patients suffering from DSM-III obsessive-compulsive disorder. The study period was 12 weeks, and the maximum doses used (from the fifth week on) were 225 mg/day for clomipramine (14 patients) and 75 mg/day for phenelzine (12 patients); four patients dropped out. Obsessive symptoms improved significantly in both drug groups, but there was no significant difference between groups. Depressive symptoms improved before obsessive ones.